KPRX
Price
$2.49
Change
+$0.13 (+5.51%)
Updated
Aug 11, 04:25 PM (EDT)
Capitalization
7.18M
NBY
Price
$0.60
Change
+$0.01 (+1.69%)
Updated
Aug 11, 04:54 PM (EDT)
Capitalization
3.45M
Interact to see
Advertisement

KPRX vs NBY

Header iconKPRX vs NBY Comparison
Open Charts KPRX vs NBYBanner chart's image
Kiora Pharmaceuticals
Price$2.49
Change+$0.13 (+5.51%)
Volume$1.6K
Capitalization7.18M
NovaBay Pharmaceuticals
Price$0.60
Change+$0.01 (+1.69%)
Volume$324
Capitalization3.45M
KPRX vs NBY Comparison Chart in %
Loading...
KPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KPRX vs. NBY commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KPRX is a StrongBuy and NBY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (KPRX: $2.36 vs. NBY: $0.59)
Brand notoriety: KPRX and NBY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KPRX: 132% vs. NBY: 81%
Market capitalization -- KPRX: $7.18M vs. NBY: $3.45M
KPRX [@Biotechnology] is valued at $7.18M. NBY’s [@Biotechnology] market capitalization is $3.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KPRX’s FA Score shows that 2 FA rating(s) are green whileNBY’s FA Score has 2 green FA rating(s).

  • KPRX’s FA Score: 2 green, 3 red.
  • NBY’s FA Score: 2 green, 3 red.
According to our system of comparison, NBY is a better buy in the long-term than KPRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KPRX’s TA Score shows that 3 TA indicator(s) are bullish while NBY’s TA Score has 4 bullish TA indicator(s).

  • KPRX’s TA Score: 3 bullish, 6 bearish.
  • NBY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, NBY is a better buy in the short-term than KPRX.

Price Growth

KPRX (@Biotechnology) experienced а -7.09% price change this week, while NBY (@Biotechnology) price change was -0.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.22%. For the same industry, the average monthly price growth was +31.78%, and the average quarterly price growth was +19.63%.

Industries' Descriptions

@Biotechnology (+22.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KPRX($7.18M) has a higher market cap than NBY($3.45M). KPRX has higher P/E ratio than NBY: KPRX (3.67) vs NBY (0.02). NBY YTD gains are higher at: -1.414 vs. KPRX (-28.485). NBY has higher annual earnings (EBITDA): -6.8M vs. KPRX (-9.57M). KPRX has more cash in the bank: 24.1M vs. NBY (8.47M). KPRX has less debt than NBY: KPRX (159K) vs NBY (1.13M). NBY has higher revenues than KPRX: NBY (9.78M) vs KPRX (0).
KPRXNBYKPRX / NBY
Capitalization7.18M3.45M208%
EBITDA-9.57M-6.8M141%
Gain YTD-28.485-1.4142,014%
P/E Ratio3.670.0215,103%
Revenue09.78M-
Total Cash24.1M8.47M285%
Total Debt159K1.13M14%
FUNDAMENTALS RATINGS
KPRX vs NBY: Fundamental Ratings
KPRX
NBY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9713
PRICE GROWTH RATING
1..100
9053
P/E GROWTH RATING
1..100
151
SEASONALITY SCORE
1..100
n/a39

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBY's Valuation (12) in the Biotechnology industry is in the same range as KPRX (21) in the Pharmaceuticals Other industry. This means that NBY’s stock grew similarly to KPRX’s over the last 12 months.

NBY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as KPRX (100) in the Pharmaceuticals Other industry. This means that NBY’s stock grew similarly to KPRX’s over the last 12 months.

NBY's SMR Rating (13) in the Biotechnology industry is significantly better than the same rating for KPRX (97) in the Pharmaceuticals Other industry. This means that NBY’s stock grew significantly faster than KPRX’s over the last 12 months.

NBY's Price Growth Rating (53) in the Biotechnology industry is somewhat better than the same rating for KPRX (90) in the Pharmaceuticals Other industry. This means that NBY’s stock grew somewhat faster than KPRX’s over the last 12 months.

KPRX's P/E Growth Rating (1) in the Pharmaceuticals Other industry is somewhat better than the same rating for NBY (51) in the Biotechnology industry. This means that KPRX’s stock grew somewhat faster than NBY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KPRXNBY
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
79%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 25 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
82%
Aroon
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
KPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PUMP4.820.20
+4.33%
ProPetro Holding Corp
NCI1.82N/A
N/A
Neo-Concept International Group Holdings Limited
ACM118.43-0.78
-0.65%
Aecom
CPRI19.70-1.07
-5.15%
Capri Holdings Limited
CHRS0.82-0.06
-7.13%
Coherus Oncology Inc

KPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, KPRX has been closely correlated with NCNA. These tickers have moved in lockstep 90% of the time. This A.I.-generated data suggests there is a high statistical probability that if KPRX jumps, then NCNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KPRX
1D Price
Change %
KPRX100%
-1.26%
NCNA - KPRX
90%
Closely correlated
-1.83%
RNAC - KPRX
89%
Closely correlated
-0.09%
NBY - KPRX
89%
Closely correlated
+1.84%
WINT - KPRX
89%
Closely correlated
-6.78%
ALLR - KPRX
86%
Closely correlated
-1.66%
More

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been closely correlated with CDTX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NBY jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
+1.84%
CDTX - NBY
93%
Closely correlated
+0.44%
NCNA - NBY
93%
Closely correlated
-1.83%
WINT - NBY
92%
Closely correlated
-6.78%
TAOX - NBY
91%
Closely correlated
+3.53%
RNAC - NBY
91%
Closely correlated
-0.09%
More